Metformin as a Potential Antitumor Agent Cover

.blurhash-client-img { display: none !important; }

Metformin as a Potential Antitumor Agent

EABR. Experimental and Applied Biomedical Research

By: Andjela Petrovic, Vladimir Markovic, Veljko Maric and Nevena Gajovic

Open Access

|Nov 2022

Authors

Andjela Petrovic

Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Serbia

Vladimir Markovic

Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Serbia

Veljko Maric

Department of Surgery, Faculty of Medicine Foca, University of East Sarajevo, Foca, Bosnia and Herzegovina

Nevena Gajovic

gajovicnevena@yahoo.com

Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Serbia

DOI: https://doi.org/10.2478/sjecr-2022-0023 | Journal eISSN: 2956-2090 | Journal ISSN: 2956-0454

Journal RSS Feed

Language: English

Submitted on: Dec 27, 2021

|

Accepted on: Feb 19, 2022

|

Published on: Nov 16, 2022

Published by: University of Kragujevac, Faculty of Medical Sciences

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

antitumor immune response

Related subjects:

Clinical medicine,

Clinical medicine, other

© 2022 Andjela Petrovic, Vladimir Markovic, Veljko Maric, Nevena Gajovic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.